On November 20, Gelonghui Pharmaceutical (301075.SZ) announced that Hubei Duorui Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for tranexamic acid injections approved and issued by the State Drug Administration.
Indications for tranexamic acid injection: This product is mainly used for various types of bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis.
According to data from Mi Intranet on the competitive pattern of chemical drug terminals in urban public hospitals in China, the sales volume of tranexamic acid injections in 2020-2022 was 378.37 million yuan, 644.04 million yuan, and 795.33 million yuan in that order.